Sapra, Puja

A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth

Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 245

Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model

Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., Greenberger, L. M., & Horak, I. D. (2008) · Clinical Cancer Research

Cancer therapeutics and mechanismsNanoparticle-Based Drug Delivery

Cited by 168

Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor

Pastorino, F., Loi, M., Sapra, P., Becherini, P., Cilli, M., Emionite, L., Ribatti, D., Greenberger, L. M., Horak, I. D., & Ponzoni, M. (2010) · Clinical Cancer Research

Neuroblastoma Research and TreatmentsCancer therapeutics and mechanisms

Cited by 79

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

Sapra, P., Kraft, P., Pastorino, F., Ribatti, D., Dumble, M., Mehlig, M., Wang, M., Ponzoni, M., Greenberger, L. M., & Horak, I. D. (2011) · Angiogenesis

Cancer therapeutics and mechanismsCancer, Hypoxia, and Metabolism

Cited by 70